Evidence map›Paper›PMID 29285491›Full record

ArticleAnnals of translational medicine2017

Detection of

Jan Trøst Jørgensen, Karsten Bork Nielsen, Jens Mollerup, Anna Jepsen, Ning Go

Abstract read
In one paragraph

Article in Annals of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Annals of translational medicine · 2021
    Article
  3. Article
  4. Comparison ofComputational and structural biotechnology journal · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jan Trøst JørgensenDepartment of Companion Diagnostic Research, Dx-Rx Institute, Fredensborg, Denmark.
Karsten Bork NielsenR&D, Diagnostics and Genomics Group, Agilent Technologies Denmark Aps, Glostrup, Denmark.
Jens MollerupR&D, Diagnostics and Genomics Group, Agilent Technologies Denmark Aps, Glostrup, Denmark.
Anna JepsenR&D, Diagnostics and Genomics Group, Agilent Technologies Denmark Aps, Glostrup, Denmark.
Ning GoMedical Sciences, Amgen Inc., Thousand Oaks, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe gene mesenchymal epithelial transition factor (

methodsHere we report the

resultsThe prevalence of

conclusionsThe novel FISH assay showed a high inter-observer reproducibility both with respect to amplification status and signal distribution. Based on the finding in the study it is suggested that

Indexed as

amplificationfluorescence in situ hybridization (FISH)gastroesophageal cancerMesenchymal epithelial transition factor (MET)reproducibilitysignal distribution

Identifiers

PMID29285491
PMCPMC5733332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.